TetroMycin B, identified by its CAS number 180027-84-3, is a member of the tetracycline class of antibiotics, which are known for their broad-spectrum antibacterial properties. This compound exhibits characteristics typical of tetracyclines, including the ability to inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit. TetroMycin B is effective against a variety of Gram-positive and Gram-negative bacteria, making it a valuable agent in treating infections. It is also noted for its potential anti-inflammatory and immunomodulatory effects. The compound's structure features a naphthacene core, which is characteristic of tetracyclines, and it possesses multiple functional groups that contribute to its biological activity. TetroMycin B may also exhibit varying degrees of solubility in different solvents, influencing its pharmacokinetics and bioavailability. As with other antibiotics, the emergence of resistance is a concern, necessitating careful use and consideration in clinical settings. Overall, TetroMycin B represents a significant compound in the field of medicinal chemistry and antibiotic development.

Tetromycin B is a cysteine protease inhibitor with K
i
values of 0.62, 1.42, 32.5, and 1.59 μM for rhodesain, falcipain-2, cathepsin L, and cathepsin B, respectively. It inhibits the growth of
T. brucei in vitro
(IC
50
= 30.87 μM). Tetromycin B is also cytotoxic to HEK293T kidney cells and J774.1 macrophages (IC
50
s = 71.77 and 20.2 μM, respectively).

TetroMycin B

180027-84-3: TetroMycin B, identified by its CAS number 180027-84-3, is a member of the tetracycline class of antibiotics, which are known for their broad-spectrum antibacterial properties. This compound exhibits characteristics typical of tetracyclines, including the ability to inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit. TetroMycin B is effective against a variety of Gram-positive and Gram-negative bacteria, making it a valuable agent in treating infections. It is also noted for its potential anti-inflammatory and immunomodulatory effects. The compound's structure features a naphthacene core, which is characteristic of tetracyclines, and it possesses multiple functional groups that contribute to its biological activity. TetroMycin B may also exhibit varying degrees of solubility in different solvents, influencing its pharmacokinetics and bioavailability. As with other antibiotics, the emergence of resistance is a concern, necessitating careful use and consideration in clinical settings. Overall, TetroMycin B represents a significant compound in the field of medicinal chemistry and antibiotic development.

Tetromycin B

Tetromycin B was isolated from Streptomyces axinellae Pol001T cultivated from the Mediterranean sponge Axinella polypoides.

CAS 180027-84-3

TetroMycin B

Tetromycin B

Ref: 7W-GA9872

Tetromycin B

Ref: TM-T35748